Compare Merck & Co., Inc. (MRK) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Workday Inc — how do they compare? Merck & Co., Inc. trades at $144.59 (market cap $351.28B), while Workday Inc trades at $189.6 (market cap $45.26B). The key difference: Merck & Co., Inc. is far larger — about 7.8× Workday Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Workday Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Workday Inc for 38 Days on average.
| MRK | WDAY | |
|---|---|---|
Market Cap | $351.28B | $45.26B |
Volume | 7,969,665 | 2,342,190 |
Sector | Health | Technology |
52-Week High | $156.43 | $245.67 |
52-Week Low | $82.49 | $112.55 |
Typical Hold Time | 98 Days | 38 Days |
Enterprise Value | $398.04B | $45.63B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Workday (WDAY) trades at $184.26, down 1.23% on the day amid a broader tech selloff, with a bearish technical signal. The company shows strong revenue growth, reaching $8.45B in 2025, and has consistently beaten earnings estimates. Recent strategic moves include AI product launches and a 2.5% headcount reduction aimed at efficiency. Analyst consensus is bullish with a $202.92 price target, but negative net cash flow and high valuation ratios present risks.
The outlook for WDAY is mixed; strong fundamentals and AI integration offer growth potential, but high P/E of 38.25 and recent layoffs signal execution risks. Investors should weigh robust analyst support against valuation concerns and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
